SUNPHARMA · Sun Pharmaceutical Industries Limited · NSE · Filed 24 Jul · 1 min read

Organon Stockholders Approve Sun Pharma's Proposed Acquisition

Sun Pharma says Organon stockholders have approved the merger under which Organon would become a wholly owned subsidiary of a Sun Pharma unit.

What was filed

Sun Pharmaceutical Industries told the NSE and BSE, under Regulation 30, that stockholders of Organon & Co. have approved the proposals tied to a previously announced merger. Under that transaction, Organon is expected to become a wholly owned subsidiary of Sun Pharmaceutical Holdings USA, Inc., which the filing describes as an indirect wholly owned subsidiary of Sun Pharma.

Where the deal stands

The company called the stockholder vote an important milestone toward completing the proposed transaction, but said the acquisition remains subject to the remaining customary closing conditions, including applicable regulatory approvals. The release does not restate the deal's financial terms, pointing instead to Sun Pharma's earlier announcement dated April 27, 2026.

For a Sun Pharma holder, the stockholder vote clears one procedural condition of a cross-border acquisition, though the company notes regulatory approvals and other closing conditions remain outstanding; the release discloses no deal size or financial terms.